

# Robert F Cornell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3358583/publications.pdf>

Version: 2024-02-01

66  
papers

2,879  
citations

331670

21  
h-index

175258

52  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3513  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
2	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	7.2	385
3	Baseline cardiovascular risk assessment in clinical patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the European Society of Cardiology in collaboration with the International Society of Heart Failure. <i>European Journal of Heart Failure</i> , 2020.	7.1	364
4	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163
5	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	1.6	140
6	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1946-1955.	1.6	128
7	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	1.6	124
8	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	4.9	113
9	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 335-345.	0.4	88
10	Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2061-2068.	2.0	87
11	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2019, 134, 860-860.	1.4	80
12	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
13	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
14	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
15	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020, 190, 555-561.	2.5	36
16	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1869-1869.	1.4	36
17	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1368-1373.	2.0	29
18	Current Concepts of Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2017, 13, 409-416.	2.1	28

#	ARTICLE	IF	CITATIONS
19	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
20	Second primary malignancy after multiple myeloma—population trends and cause-specific mortality. <i>British Journal of Haematology</i> , 2018, 182, 513-520.	2.5	25
21	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 271-275.	2.5	24
22	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2588-2594.	1.3	22
23	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 45.	2.8	22
24	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	4.1	20
25	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
26	Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management. <i>Current Oncology Reports</i> , 2019, 21, 29.	4.0	19
27	Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. <i>Frontiers in Oncology</i> , 2020, 10, 815.	2.8	19
28	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
29	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 529-532.	2.0	16
30	Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 205-211.	3.0	14
31	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 186, 807-819.	2.5	14
32	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2020, 38, 353-362.	1.7	14
33	Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency. <i>Case Reports in Endocrinology</i> , 2013, 2013, 1-10.	0.4	13
34	Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma. <i>Cardio-Oncology</i> , 2017, 3, 4.	1.7	13
35	The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis. <i>British Journal of Haematology</i> , 2017, 177, 481-483.	2.5	11
36	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11

#	ARTICLE	IF	CITATIONS
37	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	11
38	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. <i>American Journal of Hematology</i> , 2019, 94, 794-802.	4.1	10
39	KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 526-535.	0.4	10
40	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	1.4	10
41	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	1.4	10
42	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645122.	2.4	9
43	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. <i>American Journal of Hematology</i> , 2016, 91, 1044-1051.	4.1	8
44	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	2.6	8
45	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1137-1146.	2.4	7
46	A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3103-TPS3103.	1.6	7
47	Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. <i>Cancer Medicine</i> , 2022, 11, 358-370.	2.8	6
48	Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1473-1477.	2.0	5
49	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara). <i>Blood</i> , 2019, 134, 1867-1867.	1.4	5
50	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. <i>Blood</i> , 2021, 138, 481-481.	1.4	5
51	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	4.1	3
52	Why Waldenström macroglobulinemia is not just another indolent lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 95-98.	1.6	2
53	Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Blood</i> , 2018, 132, 1233-1233.	1.4	2
54	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 396-396.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. Journal of Clinical Oncology, 2018, 36, 8022-8022.	1.6	2
56	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood, 2021, 138, 483-483.	1.4	2
57	Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, e204-e208.	3.5	1
58	Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis. Blood, 2015, 126, 1841-1841.	1.4	1
59	Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.. Journal of Clinical Oncology, 2020, 38, 8515-8515.	1.6	1
60	Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. BMJ Case Reports, 2019, 12, e231314.	0.5	0
61	Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood, 2011, 118, 1880-1880.	1.4	0
62	Patterns of Myeloma (MM) Progression After Autologous Transplant (AHCT) â€œ Biochemical Progression Vs. Clinical Relapse. Blood, 2011, 118, 5097-5097.	1.4	0
63	Functional improvement measured by the six-minute walk test after chemotherapy in cardiac AL amyloidosis.. Journal of Clinical Oncology, 2015, 33, e19539-e19539.	1.6	0
64	In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant. Blood, 2015, 126, 5493-5493.	1.4	0
65	Mortality of multiple myeloma diagnosed peri-hospitalization.. Journal of Clinical Oncology, 2020, 38, e20553-e20553.	1.6	0
66	Association of elevated red cell distribution width and overall survival in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8534-8534.	1.6	0